What is InxMed?
Established in late 2018, InxMed is dedicated to pioneering novel treatments targeting the stroma microenvironment and solid tumor resistance, with a particular emphasis on addressing drug resistance in anti-PD-1/PD-L1 therapies. The company operates as a China-based biotech entity with a global outlook, building a robust engine for clinical translational science and proof-of-concept studies. Its operations span across Shanghai, Beijing, Nanjing, the United States, Canada, and Australia, supported by a highly differentiated pipeline and strategic partnerships with multinational pharmaceutical giants like Merck, Roche, and Boehringer Ingelheim. This extensive network and scientific focus position InxMed at the forefront of oncology drug development.
How much funding has InxMed raised?
InxMed has raised a total of $84M across 2 funding rounds:
Series A
$19M
Series B
$65M
Series A (2020): $19M with participation from Ennovation Ventures, Grand Yangtze Capital, China Growth Capital, and InnoMed Capital
Series B (2022): $65M led by CS Capital, AIHC Fund, Hosencare Fund, Growth Fund, and eNNOVATE Health Ventures
Key Investors in InxMed
Grand Yangtze Capital
Grand Yangtze Capital is a private equity firm established in 2012, specializing in healthcare, intelligent manufacturing, and digital technology. They have a strong track record of investing in and supporting over 100 enterprises, with a focus on integrity and professionalism.
China Growth Capital
China Growth Capital is a venture capital firm based in Beijing, China, operating within the Venture Capital & Private Equity sector. They focus on identifying and nurturing promising companies within the Chinese market.
eNNOVATE Health Ventures
eNNOVATE Health Ventures is a healthcare consultancy that aids in the development and growth of new businesses within the healthcare industry, acting as a strategic advisor and thought partner.
What's next for InxMed?
The substantial enterprise-level financing and recent strategic investment provide InxMed with the necessary capital to advance its clinical pipeline and expand its research and development capabilities. This infusion of funding is anticipated to fuel the progression of its innovative therapies through critical clinical trial phases, potentially leading to accelerated market entry. The company's global presence and established collaborations suggest a strategic approach to scaling operations and solidifying its position in the competitive biotech landscape. Future endeavors will likely focus on leveraging this capital to achieve key development milestones and further its impact on treating resistant solid tumors.
See full InxMed company page
